Population pharmacokinetic modeling of benznidazole in Brazilian patients with chronic Chagas disease

The present study aimed to establish a population pharmacokinetic (PopPK) modeling of benznidazole (BZD) in Brazilian patients with chronic Chagas disease. This was part of a Brazilian prospective cohort study with eight patients diagnosed with Chagas disease during the beginning of BZD treatment up...

Descripción completa

Detalles Bibliográficos
Autores principales: Frade, Virgínia Paula, Moreira, Carlos Henrique Valente, Sabino, Ester Cerdeira, Bedor, Danilo César Galindo, Ghilard, Fábio de Rose, Oliveira, Cláudia Di Lorenzo, Sanches, Cristina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Instituto de Medicina Tropical de São Paulo 2022
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8815855/
https://www.ncbi.nlm.nih.gov/pubmed/35137898
http://dx.doi.org/10.1590/S1678-9946202264004
Descripción
Sumario:The present study aimed to establish a population pharmacokinetic (PopPK) modeling of benznidazole (BZD) in Brazilian patients with chronic Chagas disease. This was part of a Brazilian prospective cohort study with eight patients diagnosed with Chagas disease during the beginning of BZD treatment up to the 60(th) day. On the 15(th) day of treatment, a blood sampling was collected and analyzed. A one-compartment PK model was developed using Pmetrics. Patients with an average age of 50.3 (SD: 6.2) years old, 6 female patients and 2 males, 70.2 kg (14.2), receiving a 5 mg/Kg/day dose were included. PK parameters estimated for CL, V and Ka were 6.27 L/h, 38.97 L and 1.66 h-1, respectively. This is the first study to establish a population pharmacokinetic modeling of BZD in Brazilian patients with chronic Chagas disease. Therefore, further studies are needed to obtain the complete characterization of BZD pharmacokinetics.

Ejemplares similares